Home » Stocks » BDSI

BioDelivery Sciences International, Inc. (BDSI)

Stock Price: $3.22 USD -0.16 (-4.73%)
Updated May 10, 2021 2:16 PM EDT - Market open
Market Cap 340.91M
Revenue (ttm) 159.21M
Net Income (ttm) 25.98M
Shares Out 100.99M
EPS (ttm) 0.24
PE Ratio 13.42
Forward PE 7.75
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $3.22
Previous Close $3.38
Change ($) -0.16
Change (%) -4.73%
Day's Open 3.38
Day's Range 3.22 - 3.40
Day's Volume 533,632
52-Week Range 3.04 - 5.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BioDelivery (BDSI) delivered earnings and revenue surprises of -28.57% and 0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Sc...

4 days ago - GlobeNewsWire

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...

Other stocks mentioned: CODX, KMDA, SURF, VMD
2 weeks ago - GuruFocus

RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious an...

2 weeks ago - GlobeNewsWire

If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.

Other stocks mentioned: BPMC, FLGT
3 weeks ago - GuruFocus

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

BioDelivery Sciences (BDSI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

1 month ago - Zacks Investment Research

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: ADT, SWN, TRUE, WTRH
1 month ago - 24/7 Wall Street

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues.

2 months ago - Zacks Investment Research

Shares of BioDelivery Sciences Intl (NASDAQ:BDSI) rose 6.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 66.67% year over year to $0.10, which b...

2 months ago - Benzinga

On Wednesday, March 10, BioDelivery Sciences Intl (NASDAQ:BDSI) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

2 months ago - Benzinga

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

These seven penny stocks are most likely to push through the $5 mark having built a significant head of steam in the past year. The post 7 Penny Stocks Close To Busting Through the $5 Mark appeared firs...

Other stocks mentioned: LIVX, LLNW, NOK, OGI, OPK, WTRH
2 months ago - InvestorPlace

RALEIGH, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...

2 months ago - GlobeNewsWire

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory OutcomesComparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CT

3 months ago - GlobeNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: BMRN, CPRX, INVA, NVAX, VRTX, VXRT, VYGR
5 months ago - Investopedia

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...

5 months ago - GlobeNewsWire

Let's see if BioDelivery Sciences International (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.

5 months ago - Zacks Investment Research

RALEIGH, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...

5 months ago - GlobeNewsWire

BioDelivery Sciences International, Inc. (BDSI) CEO Jeff Bailey on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Total Company Net Revenue Increased 30% versus Prior Year Reaching a Record $39.4 Million

6 months ago - GlobeNewsWire

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...

6 months ago - GlobeNewsWire

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...

6 months ago - GlobeNewsWire

RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...

6 months ago - GlobeNewsWire

Investors who target growth may want to consider investing in the following small-cap stocks as they represent companies whose trailing 12-month pro forma earnings per share advanced significantly on a ...

Other stocks mentioned: ATEN, MITK
6 months ago - GuruFocus

New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) New Scientific Information Further Highlights Differentiated Clinical Profile of BEL...

7 months ago - GlobeNewsWire

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

My Pound The Table Moment For BioDelivery Sciences

8 months ago - Seeking Alpha

RALEIGH, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious ...

8 months ago - GlobeNewsWire

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues.

9 months ago - Zacks Investment Research

BioDelivery Sciences International, Inc. (BDSI) Management on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

BioDelivery (BDSI) delivered earnings and revenue surprises of -75.00% and 0.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million

9 months ago - GlobeNewsWire

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, BNFT, CLRB, LNT
9 months ago - Zacks Investment Research

RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious a...

9 months ago - GlobeNewsWire

BioDelivery Sciences: Fundamentals Continue Divergence From Share Price

9 months ago - Seeking Alpha

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

11 months ago - Zacks Investment Research

RALEIGH, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and...

11 months ago - GlobeNewsWire

BioDelivery Sciences: Undervalued $5 Biopharma Still Growing Despite COVID-19

11 months ago - Seeking Alpha

BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues.

1 year ago - Zacks Investment Research

BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 15.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Keep your eyes on these two stocks in the months to come.

Other stocks mentioned: TRIL
1 year ago - The Motley Fool

BioDelivery Sciences Strong As Ever But At Half The Price

1 year ago - Seeking Alpha

Bully For BioDelivery Sciences

1 year ago - Seeking Alpha

BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.

1 year ago - Zacks Investment Research

About BDSI

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and... [Read more...]

Industry
Biotechnology
Founded
1997
CEO
Jeffrey Bailey
Employees
176
Stock Exchange
NASDAQ
Ticker Symbol
BDSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for BDSI stock is "Strong Buy." The 12-month stock price forecast is 6.96, which is an increase of 116.15% from the latest price.

Price Target
$6.96
(116.15% upside)
Analyst Consensus: Strong Buy